Delgocitinib

Chemical compound

Delgocitinib, sold under the brand name Corectim, is a medication used for the treatment of autoimmune disorders and hypersensitivity, including inflammatory skin conditions. Delgocitinib was developed by Japan Tobacco and approved in Japan for the treatment of atopic dermatitis. In the United States, delgocitinib is in Phase III clinical trials and the Food and Drug Administration has granted delgocitinib fast track designation for topical treatment of adults with moderate to severe chronic hand eczema.

This keyword could refer to multiple things. Here are some suggestions: